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OBJECTIVES: The study objective was to examine the preva-
lence and factors associated with potential drug-drug interac-
tions on ACE Inhibitors prescription in the U.S. from
2001–2004. METHODS: This project proposed a secondary
data analysis using the U.S. National Ambulatory Medical Care
Survey (NAMCS) conducted by the National Center for Health
Statistics. A series of population weighted descriptive analyses
were performed to evaluate the prevalence of potential drug
interactions. Eisenberg’s sociologic theory was adopted to iden-
tify the potential patient and physician’s characteristics asso-
ciated with the presence of drug interactions. A weighted
multivariate logistic regression model was used to examine the
signiﬁcance of these predictor variables with 0.05 alpha level.
RESULTS: From 2001 to 2004, there were 125.6 million visits
where ACE inhibitors were prescribed for the treatment of
hypertension in the U.S., 48.1 million (38.3%) of these visits
encountered potential drug interactions. Signiﬁcant patient char-
acteristic included sex (OR = 1.57), pay type (OR =< 0.001),
region (OR = 2.41), age (P < 0.001), and number of medications
taken (P < 0.001). Signiﬁcant physician characteristics included
metropolitan region (OR = 0.22), ofﬁce setting (OR =< 0.001),
physician employment (OR =< 0.001), practice ownership (OR
=< 0.001), e-mail consultation (OR = 5.79), payment sources
(OR =< 0.001), and specialty; pediatrics (OR = 139.61), cardi-
ology (OR = 61.30), dermatology (OR =< 0.001), urology
(<0.001), and otolaryngology (OR =< 0.001). CONCLUSION:
The study reveals a very high prevalence rate (38.3%) and rec-
ognizes various patient and physician’s characteristics associated
with potential drug interactions with ACE Inhibitors. From the
public safety viewpoint, it is imperative for the interdisciplinary
health providers to identify new strategies to avoid drug inter-
actions, particularly for the patients with polypharmacy status.
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OBJECTIVES: Non-achievement of combined optimal lipid
values (OLVs) (LDL-C, HDL-C, and TG) is associated with 
an increased risk of cardiovascular events (CVE). Data compar-
ing combination lipid therapy effects on multiple lipid abnor-
malities and CVE reduction are limited. We modeled CVE risk
reduction with extended release niacin/simvastatin (ERN/S), sim-
vastatin/ezetimibe (S/E), extended release niacin (ERN), simvas-
tation (S), and ezetimibe (E), in a large managed care (MCO)
population. METHODS: Patients were selected from a 2.1
million record database if they had a lipid panel between January
1, 2000 and December 31, 2001, no concomitant lipid therapy,
and continuous eligibility for 24 months. Cardiovascular risk
and CVEs (determined by ICD-9/CPT codes, prescription
records, and ER visits/hospitalizations) for each patient were
identiﬁed, and OLV achievement was modeled using product
labeling at maximum doses (assuming additive effects for
ERN/S). Population CVE rate during 30 ± 12 months of follow-
up was 15.16% with an odds ratio 0.69 (CI: 0.61 to 0.81).
Achievement (18%) vs non-achievement (82%) of OLVs was uti-
lized to estimate CVE rates associated with modeled OLV
achievement rates. RESULTS: We analyzed 44,351 patients;
50% male, age 65 ± 13 years. Modeled lipid therapy resulted in
combined OLV achievement of: ERN/S 66.2%, S/E 48.4%, ERN
36.4%, S 46.3%, and E 18.4% (x2 p < 0.05 all vs baseline;
ERN/S vs S/E, ERN, and S; S/E vs S and E). Based upon achieve-
ment of OLV, the predicted population CVE rates were reduced
from baseline (15.16%) to: ERN/S 9.4 % (RRR: 38%), S/E
11.5% (RRR: 24%), ERN 13.0% (RRR: 14%), S 11.8% (RRR:
22%), and E 15.1% (RRR: 0.4%)(p < 0.05 for all except E vs
baseline; ERN/S vs S/E, ERN, and S; S/E vs E). CONCLUSION:
In this MCO population, OLVs were more frequently achieved
with ERN/S versus S/E, ERN, and S. Attaining combined OLVs
with combination ERN/S resulted in signiﬁcant reductions in
projected CVE rates.
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USING AN INTERNATIONAL DATABASE OF ACUTE
CORONARY EVENTS TO ASSESS TODAY’S PRACTICE
PATTERNS AND DESCRIBE TREATMENT STRATEGIES IN THE
HOSPITAL SETTING
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OBJECTIVES: To assess the current treatment of Acute Coro-
nary Syndromes in the hospital setting and determine whether
treatment would demonstrate comparable patterns around
Europe. METHODS: The IMS Acute Cardiovascular Analyzer
is an international database designed to track patients present-
ing with an ACS in Germany, France, Italy, Spain and UK.
RESULTS: A total of 8091 ACS cases were enrolled between
November 2005 and November 2006. Data were reported from
around 500 cardiologists. Baseline patient characteristics were:
female 32%, age over 65 years 43%, hypertension 68%, dys-
lipidemia 69%, diabetes 32%, obesity 29%, coronary artery
disease 12%. Most common treatments received in hospital
were: COX inhibitors 95%, Statins 86%, clopidogrel 79%, Beta-
blockers 72% and ACE inhibitors 69%. Thrombolytic agents
were administered to 32% of STEMI patients (68% in UK vs
7% in Germany) and 5% of them also received a primary PCI.
UA/NSTEMI patients had a PCI (50%) and mostly >12 hours
after onset of symptoms (66%). In Germany has the highest
number of PCIs performed within 12 hours after the acute event
(50%). Before hospital admission 25% of STEMI vs 38% of
NSTEMI/UA patients were on statins. Approximately 68% of
STEMI patients were discharged on clopidogrel and 81% on
statins. The in-hospital mortality rates were 8% (STEMI) vs 2%
(UA/NSTEMI). For the majority of the ACS patients (55%) the
length of stay in hospital was 5–10 days. CONCLUSION: These
data can be used to identify key factors determining therapeutic
decision making concerning ACS treatment in Europe.
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OBJECTIVES: Is it enough to check for statistical heterogeneity
before plunging into a meta-analysis? For example, there are
many clinical trials of rhythm control drugs for atrial ﬁbrillation
(AF), suggesting a meta-analysis is the way to go. Is it?
METHODS: A MEDLINE search yielded 347 studies, of which
20 met strict inclusion criteria. Only randomized, blinded studies
of adults with ECG-conﬁrmed AF or atrial ﬂutter recurrence
were considered. Studies had to compare antiarrhythmic agents
or antiarrhythmics with placebo. Crossover studies and studies
of AF after cardiac surgery were excluded. RESULTS: After
detailed review, we decided that, in contrast with a published
systematic review, meta-analysis was not appropriate due to
intractable heterogeneity in study designs. Although recurrence
risk differs substantially between chronic and paroxysmal AF,
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trials mixed these types in different (and even unstated) propor-
tions. Some (n = 12) required sinus rhythm for various durations
at randomization, increasing the chance of success; 4 ignored
early recurrences or allowed for recardioversion, while 16
counted every recurrence. In addition, methods used to detect
recurrence varied from ECG conﬁrmation at regularly scheduled
visits to much more sensitive trans-telephonic monitoring (n =
11), which was employed in differing ways. Furthermore, efﬁ-
cacy endpoints were affected by biased termination of follow-up,
as treatment withdrawal due to side effects leads to less detec-
tion of recurrence. Nevertheless, a published meta-analysis
ignored these differences, citing similar recurrence rates in
control groups and chi-squared tests that did not detect statisti-
cal heterogeneity. In our opinion, this does not adequately
address heterogeneity in study designs, and the resulting esti-
mates are unsuitable for economic modeling. CONCLUSION:
Strict adherence to frequentist views can lead to inappropriate
pooling of trial data and erroneous inputs for economic models.
A Bayesian perspective provides a more correct view of the
intractable study design differences.
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Center, Durham, NC, USA, 7University of Texas Southwestern
Medical Center, Dallas,TX, USA
OBJECTIVES: Educating hypertensive patients in blood pressure
management can improve clinical outcomes. The BPSZ Program
is a nationwide educational program which provides participants
with tailored educational materials in addition to a complimen-
tary trial of one of three different antihypertensive medications.
The BPSZ-BLISS study is a naturalistic study to evaluate the
effectiveness of the BPSZ program by utilizing a sub-set of the
Program participants and measuring the following: blood pres-
sure (BP) control, compliance, persistence and treatment satis-
faction. METHODS: 20,000 MDs enrolled in the BPSZ Success
Zone program were invited to participate in the study. Using an
Interactive Voice Response System (IVRS), MDs report BP and
other data at the enrollment visit and at every usual care visit up
to 12 +/−2 months; subjects self-report BPs, persistence, compli-
ance and treatment satisfaction at 3, 6 and 12 months post BPSZ
enrollment. MDs and subjects are supported by call center rep-
resentatives as needed. In addition to BPSZ program enrollment
medication, MDs prescribe anti-hypertensive medications and
schedule visits as per usual care. The General Electric Health care
database will be used as an external referent to facilitate inter-
pretation of study outcomes. RESULTS: After 12 months, 2,000
IRB approved MDs have enrolled over 10,000 subjects (48%
male; mean age 56 years; 26% newly diagnosed); 97% of MDs,
and 75% of subjects successfully entered IVRS enrollment data.
Automated IVRS validations have successfully maintained
cohort integrity and data quality (less than 5% error on key
study variables). MD and patient enrollment will continue until
April 2007; study completion is scheduled for mid 2008. CON-
CLUSION: MD and patient enrollment, and the acquisition of
outcomes data in a nationwide health education program require
innovative design and automated data management and quality
control methodologies. Strengths and weaknesses of the BPSZ-





MOBILE PHONE MESSAGE VERSUS POSTAL REMINDERS TO
INCREASE TREATMENT ADHERENCE AFTER LIPID
LOWERING THERAPY AMONG HYPERLIPIDEMIC PATIENTS IN
PRIMARY CARE
Kim YS, Cho SJ
University of Ulsan College of Medicine, Seoul, South Korea
OBJECTIVES: To compare mobile phone messaging and postal
reminders as means of increasing the attendance rate during the
ﬁrst 24 weeks of lipid-lowering therapy among hyperlipidemic
patients in primary care. METHODS: The study was a ran-
domized controlled trial of 918 patients from 19 family practice
clinics conducted between February 2003 and June 2005.
Patients were randomly assigned to receive mobile phone
message reminders, postal reminders, and control strategies. To
ascertain attendance rates, patients were regularly followed up
12 to 24 weeks after their treatment. Reminders were sent on
average at 16 weeks. The primary measure was the attendance
rate at 24 weeks. A secondary outcome was identifying the direct
cost and beneﬁts of each reminder type. RESULTS: Overall
attendance rate was 74.1%. This differed between groups, with
76.1% attendance for the mobile phone messaging group,
73.5% for postal reminders, and 72.4% for the control group.
According to a multivariate analysis, the mobile phone messag-
ing group had a signiﬁcantly higher attendance rate (OR 1.48,
95% CI: 1.01–2.16) than the control group, but the postal
reminder group (OR 1.15, 95% CI: 0.79–1.69) did not. More-
over, for one additional visit, the marginal cost of mobile phone
messaging (USD 3.1) was much lower than that of postal
reminders (USD 47.0). CONCLUSION: Mobile phone messag-
ing is a more cost-effective method to increase the attendance
rate at 24 weeks after lipid lowering therapy among hyperlipi-
demic patients.
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OBJECTIVES: To evaluate the ability of interactive voice recog-
nition (IVR) technology to improve statin adherence in a cohort
of new start patents. METHODS: Plan members were identiﬁed
based on the existence of a ﬁlled prescription for statin therapy
between May 1, 2005 and December 1, 2005 and randomized
to intervention or control group. Statin prescription claims were
evaluated through June 25, 2006 when study analysis was com-
pleted. Subjects had to be 18 years or older, continuously
enrolled in the health plan for 2 years, and new users of statin
therapy. Members enrolled in any other plan-sponsored IVR ini-
tiative were excluded from this analysis. The intervention group
received three automated phone calls; call one provided disease
state education, call two was a reﬁll reminder, and call three
addressed the importance of physician follow up. The program
provided customized interaction based on patient response,
primary vs. secondary prevention, and reﬁll behavior. Persistence
